IRIDEX Corporation (IRIX)

NASDAQ: IRIX · IEX Real-Time Price · USD
3.04
-0.05 (-1.62%)
May 18, 2022 11:10 AM EDT - Market open
Market Cap55.33M
Revenue (ttm)55.33M
Net Income (ttm)-5.61M
Shares Out18.20M
EPS (ttm)-0.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume16,665
Open3.17
Previous Close3.09
Day's Range3.00 - 3.17
52-Week Range2.88 - 9.46
Beta1.20
AnalystsBuy
Price Target9.95 (+227.3%)
Earnings DateMay 12, 2022

About IRIX

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems tha...

IndustryHealth Care Equipment & Supplies
IPO DateFeb 15, 1996
Employees119
Stock ExchangeNASDAQ
Ticker SymbolIRIX
Full Company Profile

Financial Performance

In 2021, IRIDEX's revenue was $53.90 million, an increase of 48.30% compared to the previous year's $36.35 million. Losses were -$5.23 million, -17.44% less than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for IRIX stock is "Buy." The 12-month stock price forecast is 9.95, which is an increase of 227.30% from the latest price.

Price Target
$9.95
(227.30% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates

Iridex (IRIX) delivered earnings and revenue surprises of 6.25% and 0.10%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Zacks Investment Research

Iridex Announces First Quarter 2022 Financial Results

Achieved Record First Quarter Revenue Achieved Record First Quarter Revenue

5 days ago - GlobeNewsWire

Iridex to Report First Quarter 2022 Financial Results on May 12, 2022

MOUNTAIN VIEW, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...

2 weeks ago - GlobeNewsWire

Iridex Announces the Appointment of Beverly Huss to its Board of Directors

MOUNTAIN VIEW, Calif., March 21, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...

1 month ago - GlobeNewsWire

Iridex (IRIX) Reports Q4 Loss, Tops Revenue Estimates

Iridex (IRIX) delivered earnings and revenue surprises of -36.36% and 0.51%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Iridex Announces Fourth Quarter and Full Year 2021 Financial Results

Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth Exceeds Prior Guidance with Record Fourth Quarter Revenue and 48% Full Year Revenue Growth

2 months ago - GlobeNewsWire

Iridex to Present at the 34th Annual Roth Conference

MOUNTAIN VIEW, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...

2 months ago - GlobeNewsWire

Iridex to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

MOUNTAIN VIEW, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal dis...

2 months ago - GlobeNewsWire

Iridex Announces Preliminary Operational and Financial Results for Fourth Quarter and Full Year 2021

Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth Exceeds Prior Guidance with Record Quarterly Revenue and nearly 50% Full Year Revenue Growth

4 months ago - GlobeNewsWire

Iridex Announces Third Quarter 2021 Financial Results

Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance Achieved 51% Year-over-Year Revenue Growth and Raises 2021 Revenue Guidance

6 months ago - GlobeNewsWire

Iridex (IRIX) Soars 7.3%: Is Further Upside Left in the Stock?

Iridex (IRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

6 months ago - Zacks Investment Research

Retina and Glaucoma Experts Will Present Best Practices Using Iridex Technologies at a Consensus Panel and the AAO An...

An international expert consensus panel will discuss best practices in dosing and patient selection using MicroPulse TLT on November 6, 2021

6 months ago - GlobeNewsWire

Earnings Preview: Iridex (IRIX) Q3 Earnings Expected to Decline

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

The Top 7 Micro-Cap Stocks to Buy Before 2022

Micro-cap stocks offer big growth potential, but not all opportunities are created equal. Each of these earns a Portfolio Grader “A” rating.

6 months ago - InvestorPlace

Iridex to Report Third Quarter 2021 Financial Results on November 11, 2021

MOUNTAIN VIEW, Calif., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal dis...

6 months ago - GlobeNewsWire

Iridex to Present at the Lytham Partners Fall 2021 Investor Conference

MOUNTAIN VIEW, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal di...

7 months ago - GlobeNewsWire

Is IRIDEX (IRIX) Stock a Solid Choice Right Now?

IRIDEX (IRIX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

8 months ago - Zacks Investment Research

Iridex Stock Gains After Posting Highest Sales Since 2007

Iridex Corporation (NASDAQ: IRIX) reported Q2 revenue of $13.4 million, the highest since 2007, +116% Y/Y, beating the consensus of $11.61 million. Cyclo G6 product family generated sales of $3.6 millio...

9 months ago - Benzinga

Iridex (IRIX) Reports Q2 Loss, Tops Revenue Estimates

Iridex (IRIX) delivered earnings and revenue surprises of 43.75% and 15.65%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Iridex: Q2 Earnings Insights

Shares of Iridex (NASDAQ:IRIX) moved higher by 1.4% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 145.00% over the past year to $0.09, which be...

9 months ago - Benzinga

Iridex to Present at the 2021 H.C. Wainwright Ophthalmology Virtual Conference

MOUNTAIN VIEW, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal dis...

9 months ago - GlobeNewsWire

Will Iridex (IRIX) Report Negative Q2 Earnings? What You Should Know

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Iridex Announces First Quarter 2021 Financial Results

MOUNTAIN VIEW, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX) today reported financial results for the first quarter ended April 3, 2021.

1 year ago - GlobeNewsWire

Earnings Preview: Iridex (IRIX) Q1 Earnings Expected to Decline

Iridex (IRIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Iridex (IRIX) Beats on Q4 Earnings, Revenues Increase Y/Y

Iridex's (IRIX) fourth-quarter 2020 results benefit from strong product line-up and expanding market position.

1 year ago - Zacks Investment Research